Pantoprazole

Protonix oral products are labeled for short-term healing and symptom relief of GERD-associated erosive esophagitis in adults and children age 5 and older; maintenance of healed erosive esophagitis and reduced heartburn relapse in adults; and long-term treatment of pathological hypersecretory conditions, including Zollinger–Ellison syndrome, in adults.

Maintenance trials did not extend beyond 12 months. The pediatric indication is erosive esophagitis, not every reflux symptom; other pediatric uses are not established by this label.

Protonix IV is labeled for GERD with a history of erosive esophagitis for up to 10 days in adults and up to 7 days in children age 3 months and older, and for pathological hypersecretory conditions in adults. Switch to an appropriate oral medicine as soon as tolerated. The IV label states that efficacy and safety for upper GI bleeding have not been established; that is distinct from clinician-directed off-label protocols.

Safety beyond 8 weeks is not established in children. The 40 mg packet is a fixed dose and must not be divided to make 20 mg; use an appropriate tablet or obtain a different clinician-directed plan. The table supplies no regimen for a child below 15 kg.

Swallow whole with or without food; do not split, crush, or chew. Two 20 mg tablets may replace one 40 mg tablet if swallowing the larger tablet is difficult. Antacids do not affect tablet absorption.

Take approximately 30 minutes before a meal. Sprinkle the whole packet on 1 teaspoon of applesauce and swallow within 10 minutes without chewing; follow with sips of water. Alternatively, mix the whole packet with 1 teaspoon of apple juice, stir for 5 seconds, swallow immediately, and rinse the container once or twice with apple juice to take all granules.

Do not use other foods or liquids, and do not crush or chew the granules. NG or gastrostomy administration requires apple juice and a tube of at least 16 French; follow the full label’s syringe and repeated-rinse instructions with professional guidance.

For GERD with a history of erosive esophagitis: 40 mg IV once daily, by injection over at least 2 minutes or infusion over 15 minutes, for up to 10 days. For pathological hypersecretion: 80 mg every 12 hours by either method; frequency may increase to every 8 hours according to acid output. These are professional IV regimens, not oral directions.

Stop IV treatment as soon as oral therapy is tolerated and switch within 7 days. These IV age and weight boundaries differ from the oral product. Professional preparation and line-compatibility instructions are mandatory.

Severe renal impairment does not meaningfully change pantoprazole pharmacokinetics; the reviewed labels supply no special renal reduction schedule. Hepatic impairment substantially increases exposure, although accumulation with once-daily dosing is limited. Oral doses above 40 mg/day have not been studied in hepatic impairment; do not assume the hypersecretory high-dose regimen is validated in that population.

Hypersensitivity to pantoprazole, any formulation component, or substituted benzimidazoles is a contraindication. Do not combine with rilpivirine-containing medicines.

The reviewed Protonix oral and IV labels have no boxed warning. Their renal, infection, skin, and interaction warnings still apply.

Common adult reactions include headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness, and joint pain. Pediatric oral trial reactions also included upper respiratory infection, fever, and rash. These trial observations do not establish an individual’s risk.

IV treatment can cause injection-site reactions. Its EDTA ingredient can worsen zinc deficiency in susceptible patients; consider supplementation when appropriate. Follow IV compatibility instructions, including incompatibility with Y-site midazolam and potential incompatibility with zinc-containing products. Rodent tumor findings in the oral label have uncertain relevance to human cancer.

• Rilpivirine-containing products: contraindicated. Avoid nelfinavir; consult atazanavir dosing instructions. Monitor saquinavir toxicity when relevant.
• Warfarin: possible INR or prothrombin-time elevation; monitor and adjust warfarin as needed.
• High-dose methotrexate: possible prolonged exposure and toxicity; consider a temporary PPI hold with the treating team.
• Acid-dependent absorption: review iron, azole antifungals, selected kinase inhibitors, and other affected medicines using their exact labels.
• Mycophenolate mofetil: exposure to active mycophenolic acid may decrease; use caution in transplant patients. A rejection effect is not established by the Protonix label.
• Clopidogrel: the label reports no clinically important interaction at approved pantoprazole doses; no clopidogrel dose adjustment is required on that basis.

Pantoprazole can raise chromogranin A and confound neuroendocrine-tumor testing. The label advises a clinician-directed hold of at least 14 days before testing, with repeat testing if still high and the same laboratory for serial measurements. False-positive urine THC screening has been reported; confirm positive screens using an alternative method.

Available observational human data have not shown an association with major malformations or other adverse pregnancy outcomes. Animal developmental findings include bone changes in offspring; the labels advise counseling about potential fetal harm. Review the indication and alternatives with the obstetric clinician rather than asserting proven safety.

Pantoprazole reaches milk in low amounts. The label recommends balancing maternal clinical need, breastfeeding benefits, and possible infant effects. Current LactMed expects no adverse effects from maternal 40 mg daily based on low milk exposure, while infant blood-level and outcome evidence remains limited.

Oral products are indicated from age 5 for short-term erosive esophagitis; the marketed strengths do not provide an appropriate formulation below age 5. Pediatric oral maintenance or hypersecretory indications are not established. IV has a separate GERD/history-of-EE indication from age 3 months. Follow its distinct weight boundaries and 7-day limit.

Older adults had generally comparable short-term efficacy and safety in the oral trials; assess comorbidity, fracture risk, and persistent symptoms rather than making an age-only dosing change.

Renal impairment does not eliminate the possibility of PPI-associated acute nephritis. Hepatic impairment increases exposure; high oral doses above 40 mg/day are not studied in that group. Review prolonged or intensive dosing with the treating clinician.

Pantoprazole covalently binds gastric parietal-cell H+/K+-ATPase, inhibiting the final step in basal and stimulated acid secretion. The effect persists beyond 24 hours at studied doses despite a short circulating half-life.

Absorption

Enteric coating delays tablet absorption until after gastric transit. Tablet peak concentration is about 2.5 hours; bioavailability about 77%.

Metabolism

Extensive hepatic metabolism, principally CYP2C19 with additional CYP3A4 pathways.

Elimination

Terminal plasma half-life about 1 hour in normal metabolizers; metabolites are eliminated mainly in urine. Hepatic impairment and poor CYP2C19 metabolism prolong exposure.

• Confirm the indication and planned review date; assess symptom response and relapse, with diagnostic follow-up for persistent or recurrent symptoms.
• Assess magnesium before and periodically during prolonged therapy or with digoxin/diuretics when appropriate; assess magnesium and calcium with preexisting hypocalcemia risk.
• Evaluate B12 deficiency when suggestive symptoms occur during long-term therapy; assess fracture risk and possible nephritis or persistent diarrhea.
• Monitor INR with warfarin; coordinate methotrexate, transplant-drug, and diagnostic-testing plans. Follow IV site reactions and zinc risk during IV treatment.

• Keep tablets and granules intact; use the formulation-specific meal and mixing instructions. Do not split a granule packet for a smaller dose.
• Take the missed oral dose when remembered unless nearly time for the next; skip then, and do not take two doses together.
• Report persistent watery diarrhea, reduced urine, severe or blistering rash, sun-sensitive rash or joint pain, or symptoms suggesting low magnesium such as palpitations or muscle spasms.
• Seek emergency care for serious allergy or severe acute symptoms. Discuss the need for continued treatment and all prescription/OTC medicines at follow-up.

Generic tablets may differ in appearance. A photograph alone cannot safely identify a medicine.

Dosage form / strength

Delayed-release oral tablet · 40 mg

Label packager

Wyeth Pharmaceuticals LLC, a Pfizer subsidiary

Appearance

Yellow, oval, biconvex

Imprint

PROTONIX in brown ink on one side

Example package NDC

0008-0841-81 · bottle of 90

Delayed-release tablets

20 and 40 mg

Delayed-release granules

40 mg per fixed-dose packet; enteric-coated pale yellowish to dark brownish granules

IV powder

40 mg per single-dose vial; white to off-white freeze-dried powder for reconstitution and dilution

Oral products: 20–25°C (68–77°F), permitted excursions 15–30°C (59–86°F). Prepare granules only when ready to take the dose. Unopened IV vials: same temperature range and protect from light. IV reconstitution, dilution, compatibility, and storage times vary by administration method; use the exact professional label.